NASDAQ: FHTX - Foghorn Therapeutics Inc.

छह महीने के लिए लाभप्रदता: +44.15%
सेक्टर: Healthcare

पदोन्नति कार्यक्रम Foghorn Therapeutics Inc.


कंपनी के बारे में

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

अधिक जानकारी
It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Выручка 0.00043
EBITDA -0.0499
Число акций ао 0.04197 млрд
P/S 1892.59
P/BV 5.57
EV/EBITDA -0.033
Цена ао 6.07
ISIN US3441741077
Сайт https://foghorntx.com
Валюта usd
IPO date 2020-10-23
Sector Health Care
Industry Biotechnology
Валюта отчета usd
प्रति दिन मूल्य परिवर्तन: 0% (7.64)
प्रति सप्ताह मूल्य परिवर्तन: +5.23% (7.26)
प्रति माह मूल्य परिवर्तन: -21.4% (9.72)
3 महीने में कीमत में बदलाव: +26.49% (6.04)
छह महीने में कीमत में बदलाव: +44.15% (5.3)
प्रति वर्ष मूल्य परिवर्तन: +139.12% (3.195)
3 वर्षों में मूल्य परिवर्तन: -42.43% (13.27)
वर्ष की शुरुआत से मूल्य परिवर्तन: +92.93% (3.96)

बहुत मूल्यवान समझना

नाम अर्थ श्रेणी
P/S 8.16 1
P/BV -3.61 0
P/E 0 0
EV/EBITDA -2.45 0
कुल: 3.88

क्षमता

नाम अर्थ श्रेणी
ROA, % -34.42 0
ROE, % 127.51 10
कुल: 3.33

लाभांश

नाम अर्थ श्रेणी
Div yield, % 0 0
DSI 0 0
कुल: 0

कर्तव्य

नाम अर्थ श्रेणी
Debt/EBITDA -0.4542 10
कुल: 10

विकास का आवेग

नाम अर्थ श्रेणी
लाभप्रदता Revenue, % 7843.02 10
लाभप्रदता Ebitda, % 98.89 9
लाभप्रदता EPS, % 0.2094 1
कुल: 7.8

कार्यवाही की तिथि प्रकटीकरण तिथि अंदरूनी सूत्र प्रकार कीमत आयतन मात्रा तक शेयर करें, % बाद में शेयर करें, % दस्तावेज़
23.09.2024 24.09.2024 Costa Carlos
Chief People Officer
बिक्री 10.17 8 716 857 0 0 जोड़ना
23.09.2024 24.09.2024 Costa Carlos
Chief People Officer
खरीदना 3.72 3 188 857 0 0 जोड़ना
20.09.2024 24.09.2024 Costa Carlos
Chief People Officer
बिक्री 10.04 358 990 35756 0 -0.09 जोड़ना
20.09.2024 24.09.2024 Costa Carlos
Chief People Officer
खरीदना 3.72 133 012 35756 0 0.09 जोड़ना
18.09.2024 20.09.2024 Costa Carlos
Chief People Officer
बिक्री 10.05 116 319 11574 0 -0.03 जोड़ना
18.09.2024 20.09.2024 Costa Carlos
Chief People Officer
खरीदना 3.72 43 055 11574 0 0.03 जोड़ना

संस्थानों आयतन शेयर करना, %
Flagship Pioneering Inc. 12674120 29.78
FMR, LLC 2810009 6.6
Raymond James & Associates, Inc. 2068387 4.86
Euclidean Capital LLC 1573761 3.7
Blackrock Inc. 1305868 3.07
Vanguard Group Inc 1025113 2.41
Artal Group S.A. 720720 1.69
Point72 Asset Management, L.P. 540000 1.27
Alphabet Inc. 500901 1.18
Geode Capital Management, LLC 448350 1.05

ETF शेयर करना, % वर्ष के लिए लाभप्रदता, % लाभांश, %
Avantis U.S. Equity ETF 0.0004 32.224830464267 1.59151
Range Cancer Therapeutics ETF 2.15956 47.24446537918 0.11955
ProShares Hedge Replication ETF 0.00149 5.9237999659878 1.47892
iShares Micro-Cap ETF 0.06408 36.318555985322 1.54048
iShares Russell 2000 Growth ETF 0.01111 38.042556988 0.6026
ProShares UltraPro Russell2000 0.00545 89.821266282945 1.47873
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 Growth ETF 0.01 39.350070246167 0.60264
Vanguard Russell 2000 ETF 0.01 35.648084105685 1.48801



पर्यवेक्षक नौकरी का शीर्षक भुगतान जन्म का साल
Mr. Adrian H. B. Gottschalk President, CEO & Director 784.65k 1976 (48 साल)
Dr. Steven F. Bellon Ph.D. Chief Scientific Officer 572.6k 1965 (59 साल)
Mr. Michael J. LaCascia Chief Legal Officer 565.5k 1965 (59 साल)
Dr. Gerald R. Crabtree M.d. Founder & Member of Scientific Advisory Board N/A
Mr. Saurabh Sewak Ph.D. Vice President of Corporate Development N/A
Mr. Carlos Costa Chief People Officer N/A 1973 (51 वर्ष)
Dr. Alfonso Quintas Cardama M.D. Chief Medical Officer 300.16k 1971 (53 वर्ष)
Ms. Karin Hellsvik VP of Corporate Affairs & Investor Relations N/A
Mr. Kristian Humer M.B.A. Chief Financial Officer N/A 1976 (48 साल)
Dr. Anna Rivkin Ph.D. Chief Business Officer

पता: United States, Cambridge. MA, 500 Technology Square - Google मानचित्र में खोलें, यांडेक्स मानचित्र खोलें
वेबसाइट: https://foghorntx.com